Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Myelogenous Leukemia, Acute
About this trial
This is an interventional treatment trial for Myelogenous Leukemia, Acute focused on measuring AML, acute myelogenous leukemia, gefitinib, Iressa
Eligibility Criteria
Inclusion Criteria: Patients must have pathologically documented acute myelogenous leukemia and either not be a candidate for myelosuppressive chemotherapy due to age or comorbid disease; or have relapsed acute myelogenous leukemia or be refractory to standard therapy and not likely to require cytoreductive therapy within 30 days. ECOG performance status 0, 1 or 2 Age > 18 years Adequate kidney and hepatic function Greater than 4 weeks from any chemotherapy, radiotherapy, immunotherapy, or systemic steroid therapy with the exception of hydroxyurea. Greater than 2 months following bone marrow or peripheral blood stem cell transplantation or donor lymphocyte infusion. Exclusion Criteria: Uncontrolled active infection Urgent need for cytoreductive chemotherapy, surgery, or radiotherapy Current chemotherapy or chemotherapy within the last 4 weeks. Pregnancy or nursing mothers Infection with HIV
Sites / Locations
- Dana-Farber Cancer Institute
Arms of the Study
Arm 1
Experimental
Gefitinib (Iressa)
All patients will receive Gefitinib (Iressa) at a dose of 750 mg orally (three 250 mg tabs) each day.